New Jersey-based pharmaceutical manufacturer agrees to pay over $2 million to settle allegations
U.S. Attorney Philip Sellinger announced the deal settles allegations Novel Laboratories violated the Controlled Substances Act.
Share:
More Stories
A drug manufacturer based in Somerset has agreed to pay $2.25 million to the federal government.
U.S. Attorney Philip Sellinger announced Wednesday that the deal settles allegations Novel Laboratories violated the Controlled Substances Act.
Officials say a Drug Enforcement Administration investigation revealed that Novel Laboratories failed to account for large amounts of oxycodone, hydrocodone and temazepam over a two-year period beginning in 2019.
